You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2026

Claims for Patent: 10,702,521

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,702,521

Title:	Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
Abstract:	The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or
Inventor(s):	Katherine Louisa Widdowson
Assignee:	GlaxoSmithKline Intellectual Property Development Ltd
Application Number:	US15/505,715
Patent Claims:	1. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl{methyl)-1,2-dihydro-3H,8H-2a,5,8triazaacenaphthylene-3,8-dione as shown below: or a pharmaceutically acceptable salt thereof. 2. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: 3. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: or a pharmaceutically acceptable salt thereof. 4. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and 2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: 5. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: or a pharmaceutically acceptable salt thereof. 6. The method according to claim 5, which comprises administering to the subject (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: 7. The method according to claim 5, wherein the pharmaceutically acceptable salt is an acid addition salt formed from an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, maleic acid, citric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, and tartaric acid. 8. The method according to claim 5, wherein the pharmaceutically acceptable salt is an acid addition salt formed from methanesulfonic acid. 9. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a mesylate salt of (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: 10. A method for treating Neisseria gonorrhoeae infection in a subject in need thereof, which comprises administering to the subject a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione as shown below: or a pharmaceutically acceptable salt thereof. 11. The method according to claim 10, wherein the pharmaceutically acceptable salt is an acid addition salt formed from an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, fumaric acid, succinic acid, maleic acid, citric acid, benzoic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, and tartaric acid. 12. The method according to claim 10, wherein the pharmaceutically acceptable salt is an acid addition salt formed from methanesulfonic acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.